Robotic Surgery and Regulatory Strategy: What FDA’s New Draft Guidance Signals for Medical Device Developers

Robotic surgery continues to advance, bringing together sophisticated hardware, software, user interfaces, surgical instruments, and increasingly complex clinical applications.

For medical device developers, this complexity creates an equally important regulatory challenge: building an evidence strategy that evolves alongside the technology.

In September 2026, the U.S. Food and Drug Administration (FDA) issued the draft guidance Robotically-Assisted Surgical Devices – Premarket Submissions, providing recommendations for certain robotically-assisted surgical devices (RASDs).

The guidance reaches well beyond the contents of a regulatory submission. It addresses interconnected considerations across device design, nonclinical performance testing, software, cybersecurity, human factors, training, clinical evidence, labeling, and other areas.

For development organizations, this reinforces an important principle: sophisticated medical technologies require an integrated approach to regulatory strategy and program execution.

Understanding the Scope of the Draft Guidance

FDA describes the RASDs addressed by the draft guidance as teleoperated, software-controlled systems incorporating robotic technologies and subassemblies that assist qualified practitioners in positioning and controlling surgical instruments during open, minimally invasive, or endoluminal procedures. The term “teleoperated” is important. The draft guidance should not be interpreted as establishing a regulatory framework for fully autonomous robotic surgery. Rather, it provides FDA’s current recommendations for certain RASDs in which qualified practitioners control the surgical system. That distinction becomes increasingly important as robotic technologies move toward greater levels of automation and remote operation.

An Integrated Development Challenge

One of the most significant aspects of the draft guidance is the breadth of evidence that may contribute to a RASD premarket submission. Depending on the device, intended use, and proposed indications, developers may need to address device and system characteristics, bench and nonclinical performance, software verification and validation, cybersecurity, risk management, training, human factors, electrical safety and electromagnetic compatibility, biocompatibility, sterilization and reprocessing, nonclinical in vivo evaluation, clinical evidence, and labeling.

These activities should not be treated as isolated regulatory deliverables. They are interconnected development workstreams. A design decision may affect risk controls. Risk controls can influence software requirements and verification activities. Changes to a user interface may affect human factors. Intended use and proposed indications can influence clinical evidence requirements. Clinical results may ultimately affect labeling.

When these dependencies are not recognized early, organizations risk identifying evidence gaps only after significant development work has already been completed.

Software as Part of the Regulatory Evidence Strategy

Software is fundamental to the operation of robotically-assisted surgical systems, and FDA’s draft guidance places significant attention on software documentation, verification, and validation.

For RASDs, FDA states that device software functions will generally warrant an Enhanced Documentation Level under its existing device software guidance. If a developer believes a Basic Documentation Level is appropriate, FDA recommends providing a scientific explanation supporting that rationale based on the risks associated with the software functions and intended use.

The draft guidance also discusses verification and validation at unit, integration, and full-system levels, along with traceability between software requirements, design, testing, and risk controls. For development teams, software planning cannot operate independently from system engineering, risk management, regulatory strategy, and verification and validation. The evidence ultimately needs to demonstrate the performance and safety of the complete system.

Human Factors Should Begin Early

Human factors is another area where early integration is critical.

FDA recommends that human factors evaluations for RASDs begin early in the device design process and occur iteratively. This is particularly relevant for robotic systems because multiple user groups may interact with the same device, including surgeons, bedside assistants, surgical scrub nurses, and other operating-room personnel.

Developers need to understand how intended users interact with the system, identify use-related hazards, implement appropriate risk controls, and ultimately demonstrate that the user interface supports safe and effective use under expected conditions.

Human factors validation should therefore not be treated simply as a study conducted shortly before submission. Formative evaluations and usability considerations should inform design decisions throughout development, with the final validation building upon that earlier work.

Verification and Validation Should Reflect Intended Use

FDA recommends that nonclinical performance testing simulate the worst-case conditions a device is likely to encounter during clinical use. Bench testing should also be representative of typical clinical use and demonstrate device functionality while verifying relevant design inputs and outputs. For software-controlled systems, FDA recommends full-system testing using objective performance metrics and a rationale explaining how the testing represents real-world use cases. This highlights the importance of a verification and validation strategy that does more than assemble individual protocols.

Testing should be connected to requirements, risks, intended use, and the regulatory evidence strategy. Development teams should understand what each activity demonstrates, which risks it addresses, why the test conditions are appropriate, and how the resulting evidence contributes to the overall submission. That traceability becomes increasingly important as system complexity increases.

Clinical Evidence and Product Strategy

FDA notes that nonclinical evaluation may not always fully characterize the clinical experience associated with a robotically-assisted surgical device. Depending on the regulatory question and device, clinical evidence may come from prospective clinical investigations, real-world evidence, or clinical literature. For new RASDs that have not previously received U.S. marketing authorization, FDA states that clinical data are often needed to support premarket submissions.

Clinical evidence may also become relevant when modifications involve a new intended use, special patient populations, different technology, unresolved questions arising from nonclinical testing, or particular performance claims.

Clinical strategy should therefore be integrated into the broader development strategy.

Proposed indications, intended patient population, device functionality, training strategy, technological differences, risk profile, and proposed labeling can all influence the evidence that may ultimately be necessary. Early alignment among Regulatory, Clinical, R&D, Quality, and other functions can help ensure that evidence-generation activities support the intended regulatory objective.

Connecting the Development Workstreams

Complex medical device programs often have separate plans for software development, verification and validation, human factors, risk management, cybersecurity, clinical activities, and regulatory submissions.

Having these plans is necessary. Connecting them is equally important.

A software change that affects the user interface, for example, may also have implications for human factors, risk management, verification, training, clinical activities, and labeling. A change to intended use may affect the clinical strategy, risk analysis, testing requirements, regulatory pathway, and submission documentation.

An integrated development plan makes these dependencies visible and provides teams with a mechanism for evaluating the broader impact of important program decisions.

This is particularly important for robotic surgical technologies, where hardware, software, users, clinical workflows, and patient outcomes are closely connected.

Building Regulatory Strategy Into Development

For complex medical devices, regulatory strategy is most effective when it is built directly into the development plan. Rather than waiting until submission preparation to determine what evidence is needed, teams should understand throughout development how design decisions, requirements, risk controls, verification activities, human factors work, and clinical evidence will contribute to the regulatory submission. This approach can help organizations identify dependencies earlier, sequence activities appropriately, establish meaningful decision points, and recognize potential evidence gaps before they become submission-critical issues.

For robotic surgical systems, the integrated development plan may need to coordinate system engineering, software, cybersecurity, risk management, verification and validation, human factors, training, clinical evidence, labeling, and regulatory submission activities.

Regulatory strategy provides an important connection across these workstreams.

Looking Ahead: Autonomous and Remote Robotic Medical Devices

FDA’s September draft guidance is only one part of the broader regulatory discussion surrounding robotic medical technology. FDA has also announced a public workshop for December 2–3, 2026, titled Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities.

The workshop has a different purpose from the September RASD draft guidance.

According to FDA, the December discussion will focus specifically on robotic medical devices with autonomous and/or remote teleoperation capabilities. The agency plans to engage stakeholders on terminology, key technical considerations, probable benefits and risks, and considerations that could inform future policy development.

The distinction is important. The September draft guidance provides FDA’s current recommendations for premarket submissions for certain teleoperated RASDs.

The upcoming December workshop is a stakeholder-engagement forum exploring regulatory and technical questions associated with technologies that may incorporate greater autonomy or remote operation. The workshop should not be interpreted as establishing new FDA requirements for autonomous robotic devices. Instead, it demonstrates that FDA is actively considering how regulatory science and policy may need to evolve as robotic technologies advance.

What Medical Device Organizations Should Consider

Organizations developing robotic surgical technologies can use the draft guidance as an opportunity to evaluate the maturity and integration of their development programs.

Teams should consider whether regulatory evidence requirements are clearly reflected in development plans and whether software, system engineering, cybersecurity, risk management, verification and validation, human factors, clinical, and labeling activities have defined dependencies.

Human factors activities should begin early enough to influence design. Verification and validation should represent actual and appropriate worst-case use conditions. Clinical strategy should align with the intended use, patient population, technology, risk profile, and proposed claims.

Organizations should also consider whether important design and risk decisions can be traced through the evidence that will ultimately support the regulatory submission.

For complex technologies, identifying these connections early can reduce the likelihood of discovering significant evidence gaps late in development.

Turning Regulatory Strategy Into Program Execution

Innovation in robotic surgery continues to challenge traditional boundaries between hardware, software, clinical practice, human interaction, and regulatory evidence.

Successful development therefore requires more than understanding individual FDA recommendations. It requires translating regulatory strategy into an integrated and executable development program.

About OneGlobal Trinity M Consulting

OneGlobal Trinity M Consulting supports medical device, pharmaceutical, and biotechnology organizations navigating complex regulatory, quality, clinical, product development, validation, and program execution challenges. We work with organizations to connect strategy with execution, helping cross-functional teams align regulatory requirements, development activities, evidence needs, project timelines, risks, and key decisions throughout the product lifecycle.

Our experience across global life sciences programs enables us to support organizations as they navigate evolving regulatory expectations, complex development initiatives, and the operational challenges associated with bringing products to market.

Contact us to learn more about how OneGlobal Trinity M Consulting can support your organization.

References

• U.S. Food and Drug Administration. Robotically-Assisted Surgical Devices – Premarket Submissions. Draft Guidance for Industry and Food and Drug Administration Staff, September 2026.FDA draft guidance and official guidance page

• U.S. Food and Drug Administration. Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities. Public Workshop, December 2–3, 2026.FDA public workshop information

  
  

  Regulatory note: FDA's September 2026 document is draft guidance issued for comment purposes and is not for implementation. Draft FDA guidance represents the agency's current thinking and does not establish legally enforceable responsibilities. Companies should evaluate the recommendations in the context of their specific device, intended use, regulatory pathway, applicable regulations, recognized consensus standards, and interactions with FDA.